Work

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002

Year: 2014

Type: article

Abstract: To improve long-term outcomes for Burkitt leukaemia/lymphoma (BL) or aggressive lymphomas in adults, we assessed the benefit of adding rituximab and filgrastim support to a dose-dense modified chemotherapy regimen from the Cancer and Leukemia Group B (CALGB) 9251 trial. One hundred and five patients (aged 19-79 years) were enrolled; 27% were >60 years old; 47% had high or high-intermediate risk by International Prognostic Index (IPI) criteria. Common severe toxicities included stomatitis/upper gastrointestinal toxicity (69%), renal insufficiency (10%), neurological events (25%) and pulmonary events (18%). Seven died from treatment-related causes (one central nervous system bleed, four infections, two respiratory failure); five were >60 years old. Results in this adult population are encouraging as complete response (CR) was observed in 83% and 4-year event-free (EFS) and overall survivals (OS) were 74% and 78%, respectively. Results compare favourably to our prior chemotherapy alone study (CALGB 9251) but despite this, high-risk patients still had worse outcomes. In conclusion, short duration, intensive chemo-immunotherapy is feasible and should be considered in adults with BL as it results in high remission rates and durable remissions.

Source: British Journal of Haematology

DOI: 10.1111/bjh.12736

Authors: David A. Rizzieri, Jeffrey L. Johnson, John C. Byrd, Gerard Lozanski, Kristie A. Blum, Bayard L. Powell, Thomas C. Shea, Sreenivasa Nattam, Eva Hoke, Bruce D. Cheson, Richard A. Larson

Institutions: Duke Medical Center, The Ohio State University, Wake Forest University, University of North Carolina at Chapel Hill, Fort Wayne Medical Institute, Georgetown University, University of Chicago

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Ohio State University, Wake Forest University, University of Minnesota, National Institutes of Health, University of Illinois at Urbana-Champaign, University of North Carolina at Chapel Hill, National Cancer Institute

Awards: G10814802, G1112175344, Alliance Statistics and Data Management Center, G1486637521, G1570777714, G1689128559, G1814228702, G198474791, G199746015, G20154349, CANCER AND LEUKEMIA GROUP B, G220937036, G2223902704, G237383067, G257334932, G260759372, G2647518335, Minority Based Community Clinical Oncology Program, Cancer and Leukemia Group B Statistical Center, G3089953435, G3690325657, Cancer and Leukemia Group B: RPCI/SUNYAB, G4185274752, G4530377164, G4795678184, G6016746934, Delaware/Christiana Care Community Clinical Oncology Program, CANCER AND LEUKEMIA GROUP B, Cancer and Leukemia Group B, G6886639697, CANCER CENTER CALGB PARTICIPATION, NCTN Lead Academic Participating Sites Application, G739544170, CANCER AND LEUKEMIA GROUP B--MINNESOTA ONCOLOGY GROUP, Cancer and Leukemia Group B, Cancer and Leukemia Group B - The Ohio State University, G802218729, CANCER AND LEUKEMIA GROUP B, Alliance for Clinical Trials in Oncology Operations Center, Cancer Center Support Grant, G926666752, G973482110

OpenAlex ID: W1994482907

FWCI: 8.381

Cites: 35

Cited by: 96

Related to: 10